Opiant Pharmaceuticals, Inc.’s Partner, Adapt Pharma Limited, Submits New Drug Submission for Naloxone Nasal Spray to Health Canada Life Science Investing
Akebia Announces First Quarter 2016 Financial Results and Provides Corporate Update Biotech Investing
DelMar Pharmaceuticals Announces $5.6 Million Private Placement Of Preferred Shares Life Science Investing
Dimension Therapeutics Announces Preclinical Data Supporting Ongoing DTX101 Phase 1/2 Clinical Trial at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting Biotech Investing
Cytel Congratulates Flexion Therapeutics on Release of Phase 3 Data for Zilretta Life Science Investing
Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease Life Science Investing
KCR: Post-Authorization Study Develops Into Crucial Part of Drug Development Design Biotech Investing
OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer Life Science Investing
Inovio Pharmaceuticals Showcases its Broad Pipeline of DNA-based Immunotherapies, Vaccines and dMAbs at the American Society of Gene & Cell Therapy Life Science Investing
